Molecular Biology Reports

, Volume 36, Issue 4, pp 677–682 | Cite as

Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barré Syndrome by a proteomical approach

  • Yinrong Yang
  • Shilian Liu
  • Zhaoyu Qin
  • Yazhou Cui
  • Yanjiang Qin
  • Shumei Bai


Objective To better understand the pathophysiological mechanisms underlying Guillain-Barré Syndrome (GBS) and to ascertain the protein that presents with the most observable changes in the cerebrospinal fluid (CSF) of patients GBS. Methods we analyzed individually the proteomes of CSF of patients with GBS (the experiment group) and control subjects suffering from other neurological disorders (the control group) with two-dimensional gel electrophoresis (2-DE). The harvested gel images analyzed with software to ascertain the most significant differential protein between the two groups and identify it by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF/TOF MS). We based the enzyme linked immuno-absorbent assay (ELISA) experiment, which followed, on the results of the first experiment. Results There are six of the protein spots had significant difference in expression between two group and identification made by mass spectrography revealed that the most significant disparity was cystatin C, which was decrease in the gels. The subsequent ELISA confirmed a considerable decrease in the level of cystatin C (P < 0.01) in the patients with GBS. Conclusion The level of cystatin C decreases significantly in the CSF of GBS and calls for further studying the role in the pathogenesis of GBS.


Cerebrospinal fluid Cystatin C ELISA Guillain-Barré Syndrome Proteomic 



The authors would like to thank the financial support by Shandong University. This work was supported by grants from Qilu Hospital of Shandong University, Jinan, for collecting CSF samples and Central Laboratory, Medicinal Biotechnology Centre, Shandong Academy of Medical Sciences, Jinan, for the excellent technical assistance and Dr. Yazhou-Cui for helpful discussions on the mass spectrometry data. The authors also acknowledge GeneGo for providing access to the MetaCore software suite, and John Metz for technical assistance using the software.


  1. 1.
    Hughes RA, Cornblath DR (2005) Guillain–Barré syndrome. Lancet 366(9497):1653–1666PubMedCrossRefGoogle Scholar
  2. 2.
    Hughes RA, Rees JH (1997) Clinical and epidemiologic features of Guillain–Barré syndrome. J Infect Dis 176(Suppl 2):S92–S98PubMedCrossRefGoogle Scholar
  3. 3.
    Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain–Barre-syndrome. Ann Neurol 27(Suppl):S21–S24PubMedCrossRefGoogle Scholar
  4. 4.
    Sanchez JC, Rouge V, Pisteur M et al (1997) Improved and simplified in-gel sample application using reswelling of dry immobilized pH gradients. Electrophoresis 18(3–4):324–327PubMedCrossRefGoogle Scholar
  5. 5.
    Hochstrasser DF, Patchornik A, Merril CR (1988) Development of polyacrylamide gels that improve the separation of proteins and their detection by silver staining. Anal Biochem 173:412–423PubMedCrossRefGoogle Scholar
  6. 6.
    Neuhoff V (1988) Improved staining of proteins in polyacrylamide including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 9(6):255–262PubMedCrossRefGoogle Scholar
  7. 7.
    Turk V, Bode W (1991) The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 285(2):213–219PubMedCrossRefGoogle Scholar
  8. 8.
    Sanchez JC, Guillaume E, Lwscuyer P et al (2004) Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 4(8):2229–2230PubMedCrossRefGoogle Scholar
  9. 9.
    Aldred AR, Brack CM, Schreiber G (1995) The cerebral expression of plasma protein genes in different species. Comp Biochem Physiol B Biochem Mol Biol 111(1):1–15PubMedCrossRefGoogle Scholar
  10. 10.
    Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310(2):173–186PubMedCrossRefGoogle Scholar
  11. 11.
    Levy E, Jaskolski M, Grubb A (2006) The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol 16(1):60–70PubMedCrossRefGoogle Scholar
  12. 12.
    Nagai A, Murakawa Y, Terashima M et al (2000) Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Neurology 55(12):1828–1832PubMedGoogle Scholar
  13. 13.
    Mussap M, Plebani M (2004) Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 41(5–6):467–550PubMedCrossRefGoogle Scholar
  14. 14.
    Mangge H, Liebmann P, Tanil H (2000) Cystatin C, an early indicator for incipient renal disease in rheumatoid arthritis. Clin Chim Acta 300(1–2):195–202PubMedCrossRefGoogle Scholar
  15. 15.
    Mannes AJ, Martin BM (2003) Cystatin C as a cerebrospinal fluid biomarker for pain in humans. Pain 102(3):251–256PubMedCrossRefGoogle Scholar
  16. 16.
    Liu XD, Zeng BF, Xu JG et al (2006) Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. J Proteomics 6(3):1019–1028CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Yinrong Yang
    • 1
  • Shilian Liu
    • 1
  • Zhaoyu Qin
    • 2
  • Yazhou Cui
    • 3
  • Yanjiang Qin
    • 4
  • Shumei Bai
    • 1
  1. 1.Institute of Biochemistry and Molecular Biology, School of MedicineShandong UniversityJinanP.R. China
  2. 2.Biology Science, Department in Marine CollegeShandong University at WeihaiWeihaiP.R. China
  3. 3.Medicinal Biotechnology CentreShandong Academy of Medical SciencesJinanP.R. China
  4. 4.Qilu Hospital of Shandong UniversityJinanP.R. China

Personalised recommendations